Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | CTSV | O60911 | 4/20 | 0.39 |
| ▸ | CTSL | P07711 | 4/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5353906 | 0.86 | ADRB2 (0.39) | ADRB2 | |
| SCHEMBL5353360 | 0.86 | ADRB2 (0.39) | ADRB2 | |
| SCHEMBL5353356 | 0.85 | ADRB2 (0.41) | ADRB2 | |
| SCHEMBL5353704 | 0.84 | ADRB2 (0.51) | ADRB2 | |
| SCHEMBL5347604 | 0.82 | ADRB2 (0.44) | ADRB2 | |
| SCHEMBL5354273 | 0.82 | ADRB2 (0.44) | ADRB2 | |
| SCHEMBL6705286 | 0.76 | ADRB2 (0.43) | ADRB2 | |
| SCHEMBL6705283 | 0.75 | ADRB2 (0.50) | ADRB2 | |
| SCHEMBL5356669 | 0.74 | ADRB2 (0.62) | ADRB2 | |
| SCHEMBL5347742 | 0.74 | ADRB2 (0.45) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214698-B2 | Beta-agonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-08 | — | — | US | disclosed |
| US-20060173061-A1 | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-03 | — | — | US | disclosed |
| EP-1558583-A1 | NOVEL PHENYLETHANOLAMINE DERIVATIVES AND THE USE OF THE SAME AS BETA-3-AGONISTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| US-20040127733-A1 | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-01 | — | — | US | disclosed |
| WO-2004039784-A1 | NOVEL PHENYLETHANOLAMINE DERIVATIVES AND THE USE OF THE SAME AS BETA-3-AGONISTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173061-A1 | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions | ADRB1, ADRB2, ADRA1A | ABCB1 549/4885CTSV 3296/4885CTSL 2252/4885 |
| US-20040127733-A1 | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions | ADRB1, ADRA1A, ADRA1D | ABCB1 617/4885CTSV 3747/4885CTSL 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.